Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

NCT05276310 is registered in ClinicalTrials.gov with ImmuneOncia Therapeutics Inc. as lead sponsor.

NCT NCT05276310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05276310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
Lead sponsor
ImmuneOncia Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 2, 2022
Completion date
August 31, 2030
Enrollment
86 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer